Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model
- 1 April 2003
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 63 (4), 1548-1555
- https://doi.org/10.1046/j.1523-1755.2003.00879.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Excessive anticoagulation in patients with mild renal insufficiency receiving long‐term therapeutic enoxaparinAmerican Journal of Hematology, 2001
- Neutralization of DHG, a New Depolymerized Holothurian Glycosaminoglycan, by Protamine Sulfate and Platelet Factor 4Pathophysiology of Haemostasis and Thrombosis, 1997
- DHG, A NEW DEPOLYMERIZED HOLOTHURIAN GLYCOSAMINOGLYCAN, EXERTS AN ANTITHROMBOTIC EFFECT WITH LESS BLEEDING THAN UNFRACTIONATED OR LOW MOLECULAR WEIGHT HEPARIN, IN RATSThrombosis Research, 1996
- INTERACTION OF A NEW DEPOLYMERIZED HOLOTHURIAN GLYCOSAMINOGLYCAN WITH PROTEINS IN HUMAN PLASMAThrombosis Research, 1996
- Hyperkalemia Due to Nafamostat MesylateNew England Journal of Medicine, 1995
- Dermatan sulphate in haemodialysisThe Lancet, 1992
- Profibrinolytic activities of chemically modified heparins with very low anticoagulant activitiesThrombosis Research, 1989
- Hemorrhage during High-Risk Hemodialysis Using Controlled HeparinizationNephron, 1981
- DIALYSIS DEATH AND INCREASED FREE FATTY ACIDSThe Lancet, 1978
- Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.JCI Insight, 1977